Bridge BioResearch Ltd. Report issue

For profit Phase 1 Phase 2
Founded: London United Kingdom (2004)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2011
NCT01342497
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cantero Therapeutics, a BridgeBio company | CoA Therapeutics, Inc., a BridgeBio company | Phoenix Tissue Repair, a BridgeBio company

Active Ingredients

Drugs in Phase 2 Trials (2)

human collagen 7 (1 trial)

isoniazid (nydrazid) (1 trial)

Drugs in Phase 1 Trials (2)

bbp-671 (1 trial)

bbp-711 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Foot (Phase 2)

Foot Ulcer (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4